This EU multicenter cross-over study was designed to have 80% power to detect a 30% difference in incidence of clinically relevant Adverse Drug Reactions (ADR) within 12-week follow-up period. The study was able to show a significant 30% reduction of the risk of ADR in the patient group using a pharmacogenomic test with 12-gene panel.

A large retrospective analysis of the economic effects of the clinical implementation of a 23-gene pharmacogenetic panel in 5288 patients aged > 65 y showed a reduction of around 7000 USD per patients. The results are in line with this study and support further clinical implementation of pharmacogenetic-panel testing.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study – PubMed (

Share this post